Liquidia Technologies Inc

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The company was founded on June 28, 2020 and is headquartered in Morrisville, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Liquidia Technologies reports robust Q4 earnings, eyes YUTREPIA's market potential

Liquidia Technologies Inc (LQDA) showcased strong financial performance and promising prospects for its flagship product, YUTREPIA, in the pharmaceutical market. While facing challenges in legal proceedings and market competition, the company's focus on innovation, clinical trials, and strategic positioning bodes well for future growth and success.

Liquidia Technologies navigates legal hurdles to capitalize on YUTREPIA

Liquidia Technologies faces financial challenges with a net loss in Q1 2023 but holds a strong cash position. The success of YUTREPIA hinges on navigating legal hurdles and effectively differentiating itself in the market.

Liquidia Technologies reports solid Q2 results amidst legal victories

Liquidia Technologies Inc's Q2 2023 Earnings Call highlighted strong financials, legal victories, and strategic focus on R&D. While facing legal challenges and balancing expenses, the company remains confident in its progress. Opportunities in FDA approvals, clinical development, and strategic partnerships present avenues for growth.

Liquidia Technologies Inc (LQDA) reports strong progress and prepares for market expansion

Liquidia Technologies Inc (LQDA) made significant strides in developing inhaled treprostinil products, showcasing promising results and clear benefits.
While facing regulatory and market challenges, the company's strong commercial preparations and financial prudence position it well for future growth.
Opportunities in market expansion, successful product launches, and program development offer avenues for revenue growth and industry leadership.

Liquidia Technologies eyes FDA approval for YUTREPIA, targeting $3B market

Liquidia Technologies is poised for growth with a strong financial position and strategic focus on YUTREPIA to lead the treprostinil market.
While facing regulatory and operational challenges, the company's emphasis on addressing patient dosing effectively presents opportunities for market leadership.
The potential FDA approval of YUTREPIA post-March 31 opens doors to a $3 billion market opportunity, positioning the company for significant growth.

Liquidia Technologies reports strong Q1 performance and eyes market expansion

Liquidia Technologies Inc's Q1 2024 earnings call highlighted strong financial performance, market potential in inhaled treprostinil products, legal progress, and a focus on innovation. The company is well-positioned for commercial launch post-approval and aims to address the growing market demand for improved treatment options.

Liquidia Technologies reports Q2 results, eyes pulmonary hypertension market

Liquidia Technologies Inc reported mixed financial results for Q2 2024, with revenue of $3.7 million and a net loss.
The company's focus on YUTREPIA and L606 formulations presents promising opportunities in the pulmonary hypertension space.
Analyst inquiries highlighted key areas of interest, including product benefits, trial data, regulatory matters, and financial outlook.
With a strong cash position and ongoing FDA engagement, Liquidia is poised for potential growth and advancement in its pipeline.

Liquidia Technologies reports strong Q3 performance amidst regulatory challenges

Liquidia Technologies Inc's Q3 2024 Earnings Call highlighted strong financial performance, progress towards YUTREPIA approval, and strategic plans for product launch. Legal challenges and regulatory hurdles pose significant challenges, while opportunities for growth exist in product development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. The company was founded on June 28, 2020, and is headquartered in Morrisville, NC.

RESEARCH TRIANGLE PARK, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the closing of a debt facility on February 26, 2021, with Silicon Valley Bank, which provides Liquidia with up to $20.5 million in term loans of which the first $10.5 million was funded at closing.

Liquidia Corporation Secures $20.5 Million Debt Facility with Silicon Valley Bank

LOS ANGELES--(BUSINESS WIRE)---- $LQDA #LQDA--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Liquidia Corporation.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Liquidia Corporation and Encourages Investors with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $LQDA #LQDA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Liquidia Corporation.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Liquidia Corporation and Encourages Investors with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Liquidia Corporation (NASDAQ: LQDA) resulting from allegations that Liquidia may have issued materially misleading business information to the investing public. On November 25, 2020, Liquidia announced that the U.S. Food and Drug Administration (“FDA”) had issued a complete response letter (“CRL”) for the Company's New Drug Applicat

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Announces Investigation of Securities Claims Against Liquidia Corporation – LQDA

RESEARCH TRIANGLE PARK, N.C., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Michael Kaseta has been appointed Chief Financial Officer (CFO), effective immediately. He succeeds Steve Bariahtaris who has served as Liquidia's interim CFO since August 2020. Mr. Bariahtaris has agreed to provide assistance to the Company for a short period of time to support a smooth transition.

Liquidia Corporation Appoints Michael Kaseta Chief Financial Officer

The CRL issued to the NDA for Liquidia's (LQDA) LIQ861 stated that the FDA cannot approve the NDA in its present form

Liquidia (LQDA) PAH Drug Gets FDA's Complete Response Letter

CRL does not cite need for additional clinical studies

Liquidia Receives Complete Response Letter from FDA for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension

Merger Reinforc es Company's Commitment to Patients with PAH

Liquidia Closes Acquisition of RareGen

Liquidia Announces Results of Special Meeting of Stockholders

RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal Fowler, Chief Executive Officer of Liquidia, will present at the 2020 Jefferies Virtual London Healthcare Conference at 7:55 PM GMT (2:55 PM ET) on Thursday, November 19, 2020.

Liquidia to Present at the 2020 Jefferies Virtual London Healthcare Conference

Liquidia Technologies, Inc. (LQDA) CEO Neal Fowler on Q3 2020 Results - Earnings Call Transcript

- Raised $75 M illion through Underwritten Public Offering - Bolstered and Defended LIQ861 Patent Position - Advanced Efforts in Support of the RareGen, LLC Merger and Integration - Company to Host Webcast and Conference Call Today at 8:00 a.m. ET

Liquidia Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Company Determines Unsolicited Offer does not Constitute Superior Proposal

Liquidia Reschedules Special Meeting of Stockholders and Reaffirms Recommendation to Approve Proposed Acquisition of RareGen, LLC

Company to Host Webcast and Conference Call November 9, 2020 at 8:00a.m. ET Company to Host Webcast and Conference Call November 9, 2020 at 8:00a.m. ET

UPDATE – Liquidia to Report Third Quarter 2020 Financial Results and Provide Corporate Update on November 6, 2020

Company to Host Webcast and Conference Call November 9, 2020 at 8:00p.m. ET Company to Host Webcast and Conference Call November 9, 2020 at 8:00p.m. ET

Liquidia to Report Third Quarter 2020 Financial Results and Provide Corporate Update on November 6, 2020

Lead candidate LIQ861 has shown an equivalent safety profile to UTHR's Tyvaso, and is also a bit easier to use.

Liquidia Technologies: The Odds Of Approval Are Unclear, But The Potential Upside Makes It A Good Bet

RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that it has postponed the special meeting of stockholders, originally scheduled for October 21, 2020.

Liquidia Announces Postponement of Special Meeting of Stockholders

PTAB Institutes Inter Partes Review Proceeding Against United Therapeutics’ ‘901 Patent and Denies Institution on ‘066 Patent for Tyvaso® PTAB Institutes Inter Partes Review Proceeding Against United Therapeutics’ ‘901 Patent and Denies Institution on ‘066 Patent for Tyvaso®

Liquidia Provides Update on U.S. Patent Trial and Appeal Board Decision on Inter Partes Review of Two United Therapeutics’ Tyvaso® Patents

Dr. O’Brien Joins Liquidia with 25 Years of Medical Practice Experience in Pulmonary Critical Care Dr. O’Brien Joins Liquidia with 25 Years of Medical Practice Experience in Pulmonary Critical Care

Liquidia Names Gerald M. O’Brien, MD, as Vice President, Pulmonary Clinical Development

Special Meeting of Liquidia Technologies, Inc. Stockholders Scheduled for October 21, 2020 Special Meeting of Liquidia Technologies, Inc. Stockholders Scheduled for October 21, 2020

Liquidia Announces Special Meeting Date to Approve Proposed Acquisition of RareGen, LLC

RESEARCH TRIANGLE PARK, N.C., Aug.  28, 2020  (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application No. 16/099,135 related to LIQ861, the Company’s proprietary dry powder treprostinil currently under review with the U.S. Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension (PAH). The patent is expected to cover methods of treating patients with pulmonary hypertension through the inhalation of dry powder treprostinil.

Liquidia Announces Notice of Allowance for U.S. Patent Application Covering Methods of Treating Pulmonary Hypertension with Dry Powder Treprostinil

Steven Bariahtaris Appointed Interim Chief Financial Officer Steven Bariahtaris Appointed Interim Chief Financial Officer

Liquidia Announces Chief Financial Officer Transition

Liquidia Technologies, Inc. (LQDA) CEO Neal Fowler on Q2 2020 Results - Earnings Call Transcript

RESEARCH TRIANGLE PARK, N.C., Aug.  05, 2020  (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 10:20am Eastern time.

Liquidia to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

New data from INSPIRE LIQ861 safety and tolerability study in pulmonary arterial hypertension (PAH) patients demonstrate positive trends in exploratory endpoints, including quality of life (QoL) New data from INSPIRE LIQ861 safety and tolerability study in pulmonary arterial hypertension (PAH) patients demonstrate positive trends in exploratory endpoints, including quality of life (QoL)

News for Liquidia Technologies Inc Stock (LQDA)